Trials / Conditions / Pandemic Influenza

Pandemic Influenza

20 registered clinical trials studyying Pandemic Influenza.

Status	Trial	Sponsor	Phase
Unknown	H7HLAII DNA Influenza Vaccine NCT06046092	Oslo University Hospital	Phase 1
Completed	Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults NCT01640691	Adimmune Corporation	Phase 1 / Phase 2
Completed	Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India NCT01053143	Sanofi Pasteur, a Sanofi Company	Phase 3
Completed	Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine NCT00950456	Alachua Government Services, Inc.	—
Completed	A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents NCT00976469	Alachua Government Services, Inc.	Phase 1 / Phase 2
Completed	Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Mono NCT00971542	Novartis Vaccines	Phase 3
Completed	Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Mono NCT00971100	Novartis Vaccines	Phase 3
Completed	A/H1N1 Immunogenicity and Safety in Adults NCT00959465	Alachua Government Services, Inc.	Phase 1 / Phase 2
Completed	Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Mono NCT00971906	Novartis Vaccines	Phase 3
Completed	Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Mono NCT00970177	Novartis Vaccines	Phase 3
Completed	A/H5N1/LT Dose Ranging Study NCT00908687	Intercell USA, Inc.	Phase 2
Completed	Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant) NCT00783926	Alachua Government Services, Inc.	Phase 1
Completed	Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine NCT00535665	Sinovac Biotech Co., Ltd	Phase 2
Completed	A/H5N1 Dose Ranging Study With Adjuvant Patch NCT00532792	Intercell USA, Inc.	Phase 1
Completed	Safety, Reactogenicity and Immunogenicity of an H5N1 VLP NCT00519389	Novavax	Phase 1 / Phase 2
Completed	Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy NCT00457509	Sanofi Pasteur, a Sanofi Company	Phase 1
Completed	Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Va NCT00660257	Sinovac Biotech Co., Ltd	Phase 1
Withdrawn	A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term NCT00640874	Kirby Institute	—
Withdrawn	A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Rece NCT00640211	Kirby Institute	—
Withdrawn	A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Pr NCT00640302	Kirby Institute	—